ALIVUS vs DIVISLAB: Stock Comparison

Alivus Life Sciences Limited vs Divis Laboratories Ltd

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Divis Laboratories Ltd is the larger company by market capitalisation. Alivus Life Sciences Limited shows a lower P/E and a higher dividend yield, while Divis Laboratories Ltd shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alivus Life Sciences Limited and Divis Laboratories Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALIVUS is more favourable on 4 of 8 scored metrics and DIVISLAB on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DIVISLAB is the larger company
₹1.96 L Cr vs ₹13,944 Cr
P/E Ratio
ALIVUS has a lower P/E
24.95x vs 75.8x
P/B Ratio
ALIVUS has a lower P/B
4.23x vs 11.61x
EPS
DIVISLAB has higher earnings per share
₹96.6 vs ₹45.86
Dividend Yield
ALIVUS has a higher dividend yield
0.44% vs 0.41%
Revenue Growth (TTM YoY)
DIVISLAB has faster revenue growth
9.5% vs 6.1%
EPS Growth (TTM YoY)
ALIVUS has faster EPS growth
14.5% vs 13.6%
Net Margin
DIVISLAB has a higher net margin
24.36% vs 22.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALIVUSDIVISLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALIVUSDIVISLAB
Live Price₹1,138.5₹7,389
Day Change-0.6%0.8%
Volume51,1443.25 L
52-Week High₹1,193.9₹7,438.5
52-Week Low₹819₹5,636.5
Distance from 52W High-4.64%-0.67%

Valuation

MetricALIVUSDIVISLAB
Market Cap₹13,944 Cr₹1.96 L Cr
P/E Ratio24.95x75.8x
P/B Ratio4.23x11.61x
EPS₹45.86₹96.6
Book Value₹271.02₹631.37
Dividend Yield0.44%0.41%

Growth

MetricALIVUSDIVISLAB
Revenue Growth (TTM YoY)6.1%9.5%
EPS Growth (TTM YoY)14.5%13.6%
Qtr Sales Growth9.52%
Qtr Profit Growth13.4%

Profitability & Leverage

MetricALIVUSDIVISLAB
ROE16.5%
ROCE22%
Net Margin22.05%24.36%
Operating Margin31.4%32.6%
Debt to Equity0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALIVUSDIVISLAB
Promoter Holding74.87%51.88%
FII Holding5.54% 0.25 pp20.2% 0.09 pp
DII Holding7.18% 0.1 pp19.38% 0.16 pp
Public Holding12.41% 0.15 pp8.54% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alivus Life Sciences Limited and Divis Laboratories Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.